PGR - The Progressive Corporation
The Progressive Corp. is rated a 'Hold,' reflecting strong underwriting and durable demand but tempered by slowing premium growth and uncertain earnings momentum. PGR's Q3 2026 combined ratio improved to 88.7%, yet net premiums written grew just 4% YoY, with September monthly growth slowing to 2%. Valuation appears fair at a trailing P/E of 10.7x, but a weaker forward EPS outlook could pressure the multiple and limit upside.
Progressive Corp (NYSE:PGR) on Wednesday reported mixed third-quarter financial results.
Progressive is the leading auto insurer in the U.S., jumping into first place this year. It has beat its target goal of a 96% combined ratio for the part decade.
The Progressive's Q3 was a disappointment, but it isn't a sell signal for me. I'm still holding my shares, and I am maintaining my buy rating. Premium growth came in at 1%, auto policies dropped 31,000 in a month, and the underlying loss ratio hit 68.7, the highest in two years. The combined ratio sits at 88.7, or 91.1 without reserve releases, well under the sub-96 target. Every segment is under 96.
October's top GVAS dividend stocks offer projected net gains of 27.17% to 67.83% by October 2027, with an average estimated return of 42.47%. Thirteen of twenty-seven 'safer' lowest-priced GVAS stocks are currently fair-priced and considered ideal for purchase, balancing positive free cash flow and dividend yields. Yield-focused strategies highlight energy and shipping names, but caution is advised for stocks paying dividends from borrowed funds or with negative free cash flow margins.
Progressive's Q3 earnings beat estimates as higher premiums and an improved combined ratio boosted results, while September policy growth remained strong.
Hotter CPI Sends Futures Lower as Yields Jump.
Progressive (PGR) came out with quarterly earnings of $4.6 per share, beating the Zacks Consensus Estimate of $4.46 per share. This compares to earnings of $4.05 per share a year ago.
MAYFIELD VILLAGE, OHIO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Progressive Corporation (NYSE:PGR) today reported the following results for the month and quarter ended September 30, 2026:
Progressive's Q3 earnings are expected to rise 9.4%, aided by premium growth and higher investment income, but rising underwriting costs could weigh on results.
HOUSTON--(BUSINESS WIRE)--Corebridge Financial today announced the launch of Progressive Trigger, a first-of-its-kind index annuity interest-crediting strategy designed to help customers preserve future growth potential despite a down year. Many retirement savers understand that markets do not move in a straight line and that recoveries often take time. Progressive Trigger's built-in Memory feature is designed for this possibility, allowing eligible interest percentages to accumulate following.
Homeowners who stayed with their insurer last year paid a steep price for that loyalty, and the gap between those who shopped and those who didn't reveals something insurers would rather you not notice.
In the closing of the recent trading day, Progressive (PGR) stood at $218.98, denoting a +2.27% move from the preceding trading day.
Embedded insurance is transforming coverage distribution. Explore how PGR, CB, TRV, AIZ and ROOT are tapping into this fast-growing market.
Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS Updated Phase 1 investigator-initiated trial data to be presented, continuing to highlight encouraging clinical activity and a well-tolerated safety profile in progressive multiple sclerosis EMERYVILLE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced two abstracts selected for presentation at the MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting, taking place from October 21-23, 2026, in Toronto, Canada.
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced that it will present seven posters at the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026) taking place October 21-23, 2026, in Toronto, Canada.
Bond yields are rising fast; the market looks expensive. A bear could be on the way. Consider buying Berkshire Hathaway, Realty Income, and Progressive.
If you are looking for a reliable income stream, these two Dividend Kings should be on your watch list, if not your buy list.
Progressive (PGR) closed the most recent trading day at $210.96, moving +1.76% from the previous trading session.
Progressive (PGR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.